Patents by Inventor Yuji Haga
Yuji Haga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11962653Abstract: A device monitoring method includes: receiving a message transmitted from a first device to a second device and addressed to the second device; determining whether the message contains a device control command for controlling the second device; if the message contains the device control command, further determining whether to transmit the message to the second device based on a predetermined condition; and when the message is determined to be transmitted to the second device, transmitting the message to the second device. The predetermined condition includes a first condition that the first device is registered as a device having a predetermined function in a device list containing information about whether each of the devices is a device having the predetermined function. The message is determined to be transmitted to the second device when the predetermined condition is satisfied.Type: GrantFiled: October 27, 2021Date of Patent: April 16, 2024Assignee: PANASONIC INTELLECTUAL PROPERTY CORPORATION OF AMERICAInventors: Manabu Maeda, Tomoyuki Haga, Yuji Unagami
-
Patent number: 8821661Abstract: A method of manufacturing a honeycomb structure including a honeycomb unit includes forming a honeycomb molded body having a plurality of cells extending from a first end face to a second end face of the honeycomb molded body along a longitudinal direction of the honeycomb molded body and separated by a plurality of cell walls, placing the honeycomb molded body in a degreasing apparatus so that the first end face faces downward and the second end face faces upward, feeding introduced gas into the degreasing apparatus, degreasing the honeycomb molded body at a temperature of approximately 200° C. to approximately 400° C., and firing the degreased honeycomb molded body at a temperature of approximately 500° C. to approximately 900° C. to obtain the honeycomb unit.Type: GrantFiled: October 21, 2011Date of Patent: September 2, 2014Assignee: Ibiden Co., Ltd.Inventors: Yuji Haga, Yusuke Fujii, Tadafumi Ohashi
-
Publication number: 20120111477Abstract: A method of manufacturing a honeycomb structure including a honeycomb unit includes forming a honeycomb molded body having a plurality of cells extending from a first end face to a second end face of the honeycomb molded body along a longitudinal direction of the honeycomb molded body and separated by a plurality of cell walls, placing the honeycomb molded body in a degreasing apparatus so that the first end face faces downward and the second end face faces upward, feeding introduced gas into the degreasing apparatus, degreasing the honeycomb molded body at a temperature of approximately 200° C. to approximately 400° C., and firing the degreased honeycomb molded body at a temperature of approximately 500° C. to approximately 900° C. to obtain the honeycomb unit.Type: ApplicationFiled: October 21, 2011Publication date: May 10, 2012Applicant: IBIDEN CO., LTD.Inventors: Yuji Haga, Yusuke Fujii, Tadafumi Ohashi
-
Publication number: 20120086153Abstract: A manufacturing method of a ceramic fired body includes forming a composition of ceramic raw material containing water to make a ceramic molded body. The ceramic molded body is irradiated with a microwave under a depressurized atmosphere of about 1 KPa or more and about 50 kPa or less to dry the ceramic molded body. The ceramic molded body is fired to make the ceramic fired body.Type: ApplicationFiled: September 23, 2011Publication date: April 12, 2012Applicant: IBIDEN CO., LTD.Inventors: Ryoichi KUDO, Tsubasa Sonoo, Tadafumi Ohashi, Yuji Haga
-
Publication number: 20120035155Abstract: To provide an indole compound having a human QRFP receptor antagonistic activity and useful as a preventive or a remedy for various disorders. A compound of a formula (I) or a pharmaceutically-acceptable salt thereof is provided: [wherein, R1 represents a hydrogen atom, a halogen, a C1-6 alkyl, etc,; R2 represents a C1-6 alkyl, or a halo-C1-6 alkyl; R3 represents a hydrogen atom, a C1-6 alkyl, etc.; R4 represents a hydrogen atom, a C1-6 alkyl, a halo-C1-6 alkyl, etc.; or R3 and R4, taken together with the nitrogen atom to which they bond, form a 3- to 6-membered aliphatic nitrogen-containing hetero ring; or R3 and Y3, taken together, form —CH2—CH2—; Y1 and Y2 are both hydrogen atoms; or Y1 and Y2, taken together, form —CH2—CH2—; and Y3 represents a hydrogen atom; or Y3 and R3, taken together, form —CH2—CH2—].Type: ApplicationFiled: April 17, 2010Publication date: February 9, 2012Applicant: MSD K.K.Inventors: Yuji Haga, Sayaka Mizutani, Nagaaki Sato
-
Publication number: 20120029041Abstract: 2-Aryl imidazoline derivatives are provided that are useful as anti-obesity agents or the like. A compound represented by Formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represent a hydrogen atom, halogen, C1-6alkyl, or the like; R3a, R3b, R4a and R4b each independently represent a hydrogen atom, C1-6alkyl, or haloC1-6alkyl; and Ar represents aryl, wherein the aryl may be substituted with 1 to 3 substituents such as halogen, cyano, C1-6alkyl, haloC1-6alkyl, C1-6alkyloxy, haloC1-6alkyloxy, hydroxy, amino, monoC1-6alkylamino, diC1-6alkylamino, and C1-6alkyloxy-carbonyl.Type: ApplicationFiled: April 21, 2010Publication date: February 2, 2012Applicant: MSD K.K.Inventors: Yuji Haga, Minoru Moriya, Toshiyuki Takahashi
-
Patent number: 8044070Abstract: Provided are compounds of a formula (I) and their pharmaceutically-acceptable salts: wherein X1, X2 and X3 each independently represent N or CH; W represents the following formula (II): or the following formula (III): Y represents a group of a formula (IV): The compounds have a histamine-H3 receptor antagonistic or inverse-agonistic activity and are useful for remedy and/or prevention of obesity, diabetes, hormone secretion disorders, sleep disorders, etc.Type: GrantFiled: August 13, 2009Date of Patent: October 25, 2011Assignee: MSD K.K.Inventors: Norikazu Ohtake, Akira Naya, Yuji Haga, Makoto Jitsuoka, Takuya Suga, Ryo Yoshimoto, Shigeru Tokita, Akio Kanatani
-
Patent number: 7875633Abstract: A compound represented by the formula (I) is contained as an active ingredient: wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like, or R1 together with a nitrogen atom to which L, Z2 and R1 are attached may form an aliphatic nitrogenated heterocyclic group and R1 and R2 together with a nitrogen atom to which they are attached may form an aliphatic nitrogenated heterocyclic group; X represents a methine group or a nitrogen atom; Y represents —CH2—O—, —CH?CH— or the like; Z1 represents a single bond, a C1-4 alkylene group or the like; Z2 represents a single bond or a C1-4 alkylene group; L represents a methylene group, a C3-8 cycloalkylene group or the like; and Ar represents an aromatic carbocyclic group or the like. The compound is useful as a pharmaceutical for a central nerves system disease, a cardiovascular disease or a metabolic disease.Type: GrantFiled: August 23, 2006Date of Patent: January 25, 2011Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Akira Naya, Toshihiro Sakamoto, Yuji Haga, Norikazu Otake
-
Publication number: 20100216758Abstract: An active ingredient is a compound represented by the general formula [I]: [wherein R1 and R2 represent a lower alkyl group, a C3-6 cycloalkyl group or the like, X1 and X2 represent methine, an Ar—Y1—Y2—Y3-substituted methine or the like, however either of them is an Ar—Y1—Y2—Y3-substituted methine, X3 to X8 represent methine, —N— or the like, Y1 and Y3 represent a single bond, —O— or the like, Y2 represent a single bond, a lower alkylene group or the like, W represent —(O)—(CH2)n-(O)— or the like, n represents an integer of 1 to 4, L and Z2 represent a single bond or a methylene group, Z1 represents a single bond, a C1-4 alkylene group or the like, and Ar represents an aromatic carbocyclic group or the like]. The compound acts as a melanin-concentrating hormone receptor antagonist and useful as a therapeutic agent for obesity or the like.Type: ApplicationFiled: August 3, 2006Publication date: August 26, 2010Inventors: Makoto Ando, Etsuko Sekino, Yuji Haga, Norikazu Otake, Minoru Moriya
-
Publication number: 20100210637Abstract: Provided are compounds of a formula (I) and their pharmaceutically-acceptable salts: wherein X1, X2 and X3 each independently represent N or CH; W represents the following formula (II): or the following formula (III): Y represents a group of a formula (IV): The compounds have a histamine-H3 receptor antagonistic or inverse-agonistic activity and are useful for remedy and/or prevention of obesity, diabetes, hormone secretion disorders, sleep disorders, etc.Type: ApplicationFiled: August 13, 2009Publication date: August 19, 2010Inventors: Norikazu Ohtake, Akira Naya, Yuji Haga, Makoto Jitsuoka, Takuya Suga, Ryo Yoshimoto, Shigeru Tokita, Akio Kanatani
-
Patent number: 7732456Abstract: The invention provides pyridone derivatives represented by a general formula (I) [in the formula, R1 and R2 may be same or different and stands for H, etc., or R1 and R2 may form an aliphatic nitrogen-containing heterocyclic group together with the N to which they bind; X1-X3 may be same or different and stand for methine or N, provided not all of them simultaneously stand for nitrogen; X4-X7 may be same or different and stand for methine or N, provided that three or more of them do not simultaneously stand for N; Y1 and Y3 may be same or different and stand for single bond, —O—, —NR—, —S—, etc; Y2 stands for lower lkylene, etc.; R stands for H, etc., L stands for methylene; Z1 and Z2 may be same or different and stand for single bond or lower alkylene; or R1, L and Z2 may form an aliphatic nitrogen-containing heterocyclic group with the N to which R1 binds; and Ar stands for aromatic carbocyclic group, etc.].Type: GrantFiled: March 4, 2005Date of Patent: June 8, 2010Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Norikazu Otake, Yuji Haga, Akira Naya, Sayaka Mizutani, Akio Kanatani
-
Patent number: 7700611Abstract: The present invention relates to a process for producing crystalline trans-N-[1-(2-fluorophenyl)-S-pyrazoly]-3-ox-ospiro[6-azaisobenzofuran-1(3H),1?-cyclohexane]-4?-carboxamide and novel salts, hydrates and polymorphs thereof.Type: GrantFiled: July 24, 2006Date of Patent: April 20, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Russell R. Ferlita, Yuji Haga, Makoto Ishikawa, Keisuke Kamei, Shinji Kato, Hisaki Kojima, Aaron Moment, Nobuaki Nonoyama, Nobuya Satake, Kazuki Shigemori, Toshihiro Wada, Yaling Wang, Steven A. Weissman, Robert M. Wenslow
-
Publication number: 20090264426Abstract: Disclosed is a compound represented by the formula (I): Wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like; X1, X2 and X3 independently represent a methine group or a nitrogen atom; Y1 and Y3 independently represent a single bond, —O— or the like; Y2 represents a lower alkylene group or the like; W1 to W4 independently represent a single bond, a methylene group or the like; L represents a single bond, a methylene group or the like; Z1 and Z2 independently represent a single bond, a C1-4 alkylene group or the like; Ar1 represents an aromatic carbocyclic ring or the like; and Ar2 represents a bicyclic aromatic carbocyclic ring or the like. The compound is useful as a pharmaceutical for a central disease, a cardiovascular disease or a metabolic disease.Type: ApplicationFiled: September 5, 2006Publication date: October 22, 2009Inventors: Shunji Sakuraba, Minoru Kameda, Hiroyuki Kishino, Yuji Haga, Norikazu Otake, Minoru Moriya
-
Patent number: 7595316Abstract: Compound of the formula: (I) [wherein each of X1, X2 and X3 independently represents N or CH, W represents the formula (II):(II) or the formula (III):(III) and Y represents a group of the formula (IV):(IV)], or a pharmacologically acceptable salt thereof. This compound exhibits histamine receptor H3 antagonist or inverse agonist activity and is useful of the treatment and/or prevention of obesity, diabetes, hormonal secretion abnormality, sleep, disorder, etc.Type: GrantFiled: June 24, 2004Date of Patent: September 29, 2009Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Norikazu Ohtake, Akira Naya, Yuji Haga, Makoto Jitsuoka, Takuya Suga, Ryo Yoshimoto, Shigeru Tokita, Akio Kanatani
-
Patent number: 7589096Abstract: The present invention relates to a compound of the formula (I): wherein Az is a group comprising a monocyclic azole or a bicyclic aromatic ring of the same or different fused azoles; T, U, V and W are independently methine or nitrogen, wherein a methine may be optionally substituted by a substituent, and at least two of T, U, V and W are methine groups; and X is nitrogen or methine. The compounds of the present invention are useful as agents for the treatment of various kinds of diseases related to NPY, for example, cardiovascular disorders, nervous system disorders, genitative diseases, metabolic diseases, genital or reproductive disorders, gastro-intestinal disorders, respiratory disorders, inflammatory diseases or glaucoma, and the like.Type: GrantFiled: February 26, 2008Date of Patent: September 15, 2009Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Norikazu Otake, Yuji Haga, Makoto Jitsuoka, Akio Kanatani
-
Publication number: 20090137587Abstract: A compound represented by the formula (I) is contained as an active ingredient: wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like, or R1 together with a nitrogen atom to which L, Z2 and R1 are attached may form an aliphatic nitrogenated heterocyclic group and R1 and R2 together with a nitrogen atom to which they are attached may form an aliphatic nitrogenated heterocyclic group; X represents a methine group or a nitrogen atom; Y represents —CH2—O—, —CH?CH— or the like; Z1 represents a single bond, a C1-4 alkylene group or the like; Z2 represents a single bond or a C1-4 alkylene group; L represents a methylene group, a C3-8 cycloalkylene group or the like; and Ar represents an aromatic carbocyclic group or the like. The compound is useful as a pharmaceutical for a central nerves system disease, a cardiovascular disease or a metabolic disease.Type: ApplicationFiled: August 23, 2006Publication date: May 28, 2009Inventors: Akira Naya, Toshihiro Sakamoto, Yuji Haga, Norikazu Otake
-
Publication number: 20090124648Abstract: The present invention relates to a process for producing crystalline trans-N-[1-(2-fluorophenyl)-S-pyrazoly]-3-ox-ospiro[6-azaisobenzofuran-1(3H),1?-cyclohexane]-4?-carboxamide and novel salts, hydrates and polymorphs thereof.Type: ApplicationFiled: July 24, 2006Publication date: May 14, 2009Inventors: Russell R. Ferlita, Yuji Haga, Makoto Ishikawa, Keisuke Kamei, Shinji Kato, Hisaki Kojima, Aaron Moment, Nobuaki Nonoyama, Nobuya Satake, Kazuki Shigemori, Toshihiro Wada, Yaling Wang, Steven A. Weissman, Robert M. Wenslow
-
Publication number: 20080188507Abstract: The present invention relates to a compound of the formula (I): wherein Az is a group comprising a monocyclic azole or a bicyclic aromatic ring of the same or different fused azoles; T, U, V and W are independently methine or nitrogen, said methine being optionally substituted by a substituent, and at least two of T, U, V and W are said methine groups; and X is nitrogen or methine. The compounds of the present invention are useful as agents for the treatment of various kinds of diseases related to NPY, for example, cardiovascular disorders, nervous system disorders, genitative diseases, metabolic diseases, genital or reproductive disorders, gastro-intestinal disorders, respiratory disorders, inflammatory diseases or glaucoma, and the like.Type: ApplicationFiled: February 26, 2008Publication date: August 7, 2008Inventors: Norikazu Otake, Yuji Haga, Makoto Jitsuoka, Akio Kanatani
-
Patent number: 7365079Abstract: The present invention relates to a compound of the formula (I): wherein Az is a group comprising a monocyclic azole or a bicyclic aromatic ring of the same or different fused azoles; T, U, V and W are independently methine or nitrogen, said methine being optionally substituted by a substituent, and at least two of T, U, V and W are said methine groups; and X is nitrogen or methine. The compounds of the present invention are useful as agents for the treatment of various kinds of diseases related to NPY, for example, cardiovascular disorders, nervous system disorders, genitative diseases, metabolic diseases, genital or reproductive disorders, gastrointestinal disorders, respiratory disorders, inflammatory diseases or glaucoma, and the like.Type: GrantFiled: November 25, 2003Date of Patent: April 29, 2008Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Norikazu Otake, Yuji Haga, Makoto Jitsuoka, Akio Kanatani
-
Patent number: 7304072Abstract: Compounds represented by the general formula (I) wherein Ar1 represents an aryl or heteroaryl which may be substituted; n represents 0 or 1; T, U, V and W each independently represent a nitrogen atom or a methine group which may have a substituent selected from the group consisting of halogen, lower alkyl, hydroxy and lower alkoxy, wherein at least two of which represent said methine group; X represents methine, hydroxy substituted methine or nitrogen atom; Y represents an imino which may be substituted with lower alkyl, or oxygen; and a salt, ester or N-oxide derivative thereof. The compounds exhibit NPY antagonistic activities and are useful as agents for the treatment of various diseases related to NPY, for example, cardiovascular disorders, central nervous system disorders, metabolic diseases, sexual and reproductive dysfunctions, gastro-intestinal disorders, respiratory disorders, inflammation or glaucoma, and the like.Type: GrantFiled: August 23, 2004Date of Patent: December 4, 2007Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Takehiro Fukami, Akio Kanatani, Akane Ishihara, Yasuyuki Ishii, Toshiyuki Takahashi, Yuji Haga, Toshihiro Sakamoto, Takahiro Itoh, Masato Chiba